Author: Newsdesk

Posted on

CrowdStrike Integrates Intelligence Feeds and Automation Capabilities to Enhance Newly Introduced AWS Network Firewall

CrowdStrike Integrates Intelligence Feeds and Automation Capabilities to Enhance Newly Introduced AWS Network Firewall

New integration streamlines incident response, providing a continuous line of defense from the network to the workload against threat actors regardless of the attack vector

SUNNYVALE, Calif.–(BUSINESS WIRE)–CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a leader in cloud-delivered endpoint and workload protection, today announced it is a Launch Partner for AWS Network Firewall, a managed service that makes it easy to deploy essential network protections for all of a customer’s Amazon Virtual Private Clouds (Amazon VPCs). This integration enables customers to leverage the CrowdStrike Falcon® platform capabilities by extending threat intelligence and deployment automation for streamlined incident response and simplified operations. This development further deepens the technical collaboration between Amazon Web Services (AWS) and CrowdStrike, a pioneer of the security cloud, to offer customers enhanced solutions that protect workloads from the network to the endpoint.

An increasingly complex threat environment coupled with the widespread digital transformation that organizations have undergone has made it necessary to institute multi-layered risk-mitigation strategies to secure cloud workloads and endpoints. This latest integration from CrowdStrike for AWS allows organizations to implement a modern enterprise security approach where network-layer protection works in conjunction with cloud workload protection controls to defend against sophisticated threat activity. This allows customers to build a seamless line of defense across cloud workloads hosted in Amazon VPCs across multiple AWS accounts.

“Through our growing collaboration with AWS, CrowdStrike continues to meet the needs of today’s cloud-first businesses by providing critical security capabilities that leverage intelligence feeds, threat hunting, policy controls and streamlined incident management – all critical components of a robust cyber defense strategy,” said Michael Sentonas, CrowdStrike’s chief technology officer. “By integrating with AWS Network Firewall, we are enabling organizations to implement a holistic enterprise security strategy that provides comprehensive visibility, automation of policy and operations and shortened time to detection, from the network to the workload.”

“Organizations must deploy a multilayered security strategy in order to fortify their security posture against advanced threats from the multiple attack vectors that target their corporate networks,” said Andrew Thomas, general manager, Perimeter Protection, Amazon Web Services, Inc. “The integration of CrowdStrike Falcon intelligence feeds and automation capabilities for AWS Network Firewall advances protections for our joint customers across their AWS footprint, by providing a continuous line of defense from the network to the workload.”

The CrowdStrike Falcon integration with AWS Network Firewall offers customers the ability to export domain-based indicators of compromise (IoCs) identified through threat intelligence feeds from the CrowdStrike Falcon platform to block nefarious network activity related to malicious domains and domain-based exploitation techniques. As a result, customers can accelerate their incident response with dynamic policy creation that quickly blocks access to known compromised domains across their AWS footprint. The integration also enables users to proactively hunt for suspicious activity based on specific criteria, such as industry, threat actor or tactics, techniques and procedures (TTPs), across their Falcon managed hosts and AWS networks.

Capabilities for AWS Network Firewall:

● Dynamic Policy Creation: Leverage threat detections from the CrowdStrike Falcon platform to construct policies that secure AWS network traffic against known domain-based threats, based on industry vertical, a specific threat actor or exploitation techniques.

● Streamlined Incident Response: Create domain filtering policies based on alerts from Falcon managed hosts to secure an organization’s entire AWS footprint.

● Proactive Threat Hunting: Proactively hunt for threat activity across Falcon managed and unmanaged workloads in AWS accounts by creating firewall policies.

Amazon Linux 2 Ready designation

CrowdStrike, an AWS Advanced Technology Partner, has also achieved the Amazon Linux 2 Ready designation, part of the AWS Service Ready Program. This designation recognizes that the CrowdStrike Falcon platform has been validated to run on and support Amazon Linux 2. Shared customers can seamlessly deploy Falcon sensor and secure AWS workloads running on Linux 2 with Falcon Cloud Workload Protection product suite.

In addition to the integration for AWS Network Firewall, and the Amazon Linux 2 Ready designation, CrowdStrike recently announced expanded support for AWS Workloads and Container Deployments, including compute services AWS Graviton, Amazon Workspaces, Bottlerocket, and cloud services AWS PrivateLink and AWS Control Tower. CrowdStrike also introduced Falcon Horizon and Falcon for AWS, which provides cloud security posture management and cloud workload protection, an integration with Amazon GuardDuty, which protects against vulnerabilities, malicious activity, and unauthorized behavior, and participated in the launch of AWS Security Hub. CrowdStrike has also achieved AWS Security Competency status and is available in the AWS Marketplace.

To read more about CrowdStrike’s latest integrations for AWS, visit this blog.

For more information, see the AWS Network Firewall page.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the benefits of CrowdStrike’s collaboration and integration with AWS for organizations. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About CrowdStrike

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a global cybersecurity leader, is redefining security for the cloud era with an endpoint and workload protection platform built from the ground up to stop breaches. The CrowdStrike Falcon® platform’s single lightweight-agent architecture leverages cloud-scale artificial intelligence (AI) and offers real-time protection and visibility across the enterprise, preventing attacks on endpoints and workloads on or off the network. Powered by the proprietary CrowdStrike Threat Graph®, CrowdStrike Falcon correlates 4 trillion endpoint-related events per week in real time from across the globe, fueling one of the world’s most advanced data platforms for security.

With CrowdStrike, customers benefit from better protection, better performance and immediate time-to-value delivered by the cloud-native Falcon platform.

There’s only one thing to remember about CrowdStrike: We stop breaches.

Qualifying organizations can gain full access to Falcon Prevent™ by starting a free trial.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | Twitter

© 2020 CrowdStrike, Inc. All rights reserved. CrowdStrike, the falcon logo, CrowdStrike Falcon and CrowdStrike Threat Graph are marks owned by CrowdStrike, Inc. and registered with the United States Patent and Trademark Office, and in other countries. CrowdStrike owns other trademarks and service marks, and may use the brands of third parties to identify their products and services.

CrowdStrike, Inc.

Ilina Cashiola, 202-340-0517

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Internet Security Technology Software

MEDIA:

Posted on

Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N
PM1-mutated acute myeloid leukemia

Expanded executive team and board of directors with hiring of COO and CFO and appointment of audit committee chair, respectively

Completed upsized initial public offering of common stock on October 14, 2020, raising $28
7.5 million in gross proceeds

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third quarter 2020 financial results.

“Kronos Bio experienced transformational growth in 2020. With the acquisition of the portfolio of SYK inhibitors from Gilead Sciences, we are positioned to initiate late-stage clinical testing next year of our lead investigational therapy entospletinib in patients with newly diagnosed NPM1-mutated acute myeloid leukemia. Furthermore, in the first half of 2021, we plan to begin clinical testing of KB-0742, our CDK9 inhibitor, in patients with advanced solid tumors,” said Norbert Bischofberger, Ph.D., president and CEO. “We have expanded our leadership team and filled key roles across the organization. Additionally, with the completion of two financing rounds, including our upsized IPO, we are well-capitalized to execute on our mission to develop and deliver therapies that have the potential to change patients’ lives.”

Recent Highlights

  • In July 2020, acquired Gilead Sciences’ portfolio of spleen tyrosine kinase (SYK) inhibitors, including entospletinib, which Kronos Bio is developing as a frontline treatment for patients with NPM1-mutated acute myeloid leukemia (AML).
  • Expanded the company’s leadership team with the hiring of Barbara Kosacz, chief operating officer and general counsel, and Dr. Yasir Al-Wakeel, chief financial officer and head of corporate development, and appointed Elena Ridloff to the company’s Board of Directors as chair of the audit committee.
  • In September 2020, closed a private financing round of approximately $155.2 million of convertible notes.
  • In October 2020, completed an upsized initial public offering (IPO) of 15,131,579 of common stock, including full exercise of the underwriters’ option to purchase additional shares, resulting in gross proceeds of $287.5 million, before deducting underwriting discounts and commissions and offering expenses.
  • In October 2020, published in Cell Chemical Biology the results of a preclinical study of KB-0742, the company’s potent oral, highly selective cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. These results were previously presented at the American Association for Cancer Research Virtual Annual Meeting II in June 2020.

Third Quarter Financial Highlights

  • Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2020, cash, cash equivalents and short-term investments totaled $211.3 million, which excludes approximately $263.9 million in net proceeds from the company’s October 2020 upsized IPO.

  • R&D Expenses: Research and development expenses were $16.8 million for the third quarter of 2020, which includes $0.2 million in stock-based compensation expense.

  • G&A Expenses: General and administrative expenses were $4.1 million for the third quarter of 2020, which includes $1.0 million in stock-based compensation expense.

  • Net Loss: Net loss was $39.7 million, or $6.48 per basic and diluted share, for the quarter ended September 30, 2020. This includes a non-recurring $15.2 million non-cash change in fair value of convertible notes.

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, implied and express statements regarding intentions, beliefs, projections, outlook analyses or current expectations concerning, among other things: our expectations about timing and execution of anticipated milestones, including planned IND submissions, initiation of clinical trials and the availability of clinical data from such trials; our cash forecasts; our expectations about our partners’ and collaborators’ ability to execute key initiatives; and the ability of our lead product candidates to treat the underlying causes of their respective targets. These forward looking statements may be accompanied by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and other words of a similar meaning. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our clinical trials, strategy and future operations; the delay of any current or planned clinical trials or the development of the Company’s drug candidates, including, but not limited to entospletinib and KB-0742; the risk that the results of our clinical trials may not be predictive of future results in connection with future clinical trials; the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company’s planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the final prospectus dated October 9, 2020 and filed pursuant to Rule 424(b) under the Securities of 1933, as amended, with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Kronos Bio’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kronos Bio’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Kronos Bio explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Kronos Bio, Inc.

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)
(Unaudited)

  Three months ended September 30,   Nine months ended September 30,
  2020   2019   2020   2019
Operating expenses:              
Research and development $ 16,755     $ 3,526     $ 30,125     $ 8,698  
General and administrative 4,054     797     6,831     2,262  
Total operating expenses 20,809     4,323     36,956     10,960  
Loss from operations (20,809 )   (4,323 )   (36,956 )   (10,960 )
Other income (expense), net:              
Change in fair value of convertible notes payable (15,215 )   —     (15,215 )   —  
Interest expense (3,889 )   (1 )   (3,890 )   (3 )
Interest and other income, net 200     311     774     311  
Total other income (expense), net (18,904 )   310     (18,331 )   308  
Net loss (39,713 )   (4,013 )   (55,287 )   (10,652 )
Other comprehensive income (loss):              
Net unrealized gain (loss) on available-for-sale securities (117 )   —     65     —  
Net comprehensive loss $ (39,830 )   $ (4,013 )   $ (55,222 )   $ (10,652 )
Net loss per share, basic and diluted $ (6.48 )   $ (0.74 )   $ (9.39 )   $ (2.05 )
Weighted-average shares of common stock, basic and diluted 6,127,146     5,409,433     5,886,191     5,196,681  





Kronos Bio, Inc.

Selected Balance Sheet Data

(in thousands, except share and per share amounts)
(Unaudited)

  September 30, 2020   December 31, 2019
Cash, cash equivalents and short-term investments $ 211,265     $ 92,184  
Total assets 262,556     102,686  
Total liabilities 215,929     2,982  
Convertible preferred stock 122,907     122,907  
Total stockholders’ deficit (76,280 )   (23,203 )

Contact:

Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
[email protected]



Posted on

Semtech’s New 1N5822 QPL Schottky Diode Now Qualified to Space Grade

Semtech’s New 1N5822 QPL Schottky Diode Now Qualified to Space Grade

New JANS qualification opens this device up for sale into satellite/spacecraft applications

CAMARILLO, Calif.–(BUSINESS WIRE)–Semtech Corporation (Nasdaq: SMTC), a leading supplier of high-performance analog and mixed-signal semiconductors and advanced algorithms, announced the qualification of its new Schottky diode to space grade.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005428/en/

Semtech Hi-Rel Solutions (Graphic: Business Wire)

Semtech Hi-Rel Solutions (Graphic: Business Wire)

The new addition, JANS1N5822 (also available as JANS1N5822US in MELF surface mount packaging), is Semtech’s first Schottky diode for use in space applications. This diode will add to the range of QPL high reliability devices available from Semtech. This qualification will make Semtech the second qualified manufacturer for this highly specialized diode.

“Semtech’s new space grade qualification provides another source for this popular device to our satellite and spacecraft customer base,” said Alan Burchfield, Power and High Reliability Product Line Director for Semtech’s Wireless and Sensing Products Group. “As with the rest of the product family, this device and the die within can be used as building blocks for custom devices to match our customers’ specific needs.”

The new diode is qualified to JANS assurance level in accordance with MIL-PRF-19500 and will be available in axial and surface mount (MELF) packages. The device will be available through distribution. For pricing and purchasing options, inquire by contacting a local sales office in the U.S.

Key Specifications

  • Reverse Working Voltage VRWM = 40V
  • Output Current IO = 3A
  • Forward Voltage Drop VF = 0.5V @ 3A
  • Operating Junction Temperature Range TJ = -65C to +125C

Resources

About Semtech’s High Reliability Products

Semtech’s High Reliability Products include Qualified Products List (QPL) and non-QPL rectifiers, Schottky diodes, Transient Voltage Suppressors (including DO-160G for high speed interfaces) and Zener diodes in axial and surface-mount packages, as well as assemblies in catalog and custom configurations. A new range of Commercial Off-The-Shelf (COTS) diodes and power management devices round out the offerings. Designed to operate across a wide temperature range in unforgiving environments, these devices are ideal for aerospace, industrial and military applications.

About Semtech

Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the Nasdaq Global Select Market under the symbol SMTC. For more information, visit www.semtech.com.

Forward-Looking and Cautionary Statements

All statements contained herein that are not statements of historical fact, including statements that use the words “can be,” “will,” “designed to” or other similar words or expressions, that describe Semtech Corporation’s or its management’s future plans, objectives or goals are “forward-looking statements” and are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Semtech Corporation to be materially different from the historical results and/or from any future results or outcomes expressed or implied by such forward-looking statements. Such factors are further addressed in Semtech Corporation’s annual and quarterly reports, and in other documents or reports, filed with the Securities and Exchange Commission (www.sec.gov) including, without limitation, information under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Semtech Corporation assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law.

Semtech, and the Semtech logo are registered trademarks or service marks of Semtech Corporation.

SMTC-P

Ronda Grech

Semtech Corporation

(805) 250-1263

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Mobile/Wireless Technology Semiconductor Engineering Satellite Other Technology Aerospace Software Manufacturing Hardware

MEDIA:

Logo
Logo
Photo
Photo
Semtech Hi-Rel Solutions (Graphic: Business Wire)
Posted on

Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress’ 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings.

“We are thrilled to be recognized among an elite group of 500 companies in Deloitte’s Technology Fast 500™ for the second year in a row. We are proud of our rapid revenue growth, as generating value for our shareholders is always a top priority,” said Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer. “Our business strategy allows us to acquire and develop a broad array of new marketed products and product candidates with significant commercial and clinical potential. Through our approach, we have established a growing portfolio of five marketed products and over 25 development-stage programs that we believe will provide our company and its shareholders with a diversified long-term revenue stream.”

Now in its 26th year, the Technology Fast 500 selects companies based on percentage fiscal year revenue growth over a three-year period. Overall, the 2020 Technology Fast 500 companies achieved revenue growth ranging from 175 percent to 106,508 percent from 2016 to 2019, with a median growth rate of 450 percent. For more information about the Technology Fast 500, visit www.fast500.com.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:

Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]  



Posted on

Woodside Homes Nails Home Buyer Engagement with Medallia

Woodside Homes Nails Home Buyer Engagement with Medallia

Highlights their commitment to keeping families at the heart of their business

SAN FRANCISCO–(BUSINESS WIRE)–
Medallia (MDLA), the leader in experience management, today announced Woodside Homes, a 40-year-old home designer and builder and 28th on the Builder 2020 100 list, has selected Medallia to ensure they nail customer engagement including offering more personalized experiences along the buyer journey.

Woodside has selected Medallia Experience Cloud, Text Analytics, Conversations, Crowdicity, LivingLens and Zingle to engage with customers and understand what they need from their home designer and builder and take action to exceed expectations.

“Woodside Homes is synonymous with integrity, excellence and innovation. Their reputation doesn’t come just from their passion for home building, it also comes from a culture of customer engagement and delivering stellar experiences,” said Rory Cameron, executive vice president, corporate development for Medallia.

Follow us on LinkedIn, Twitter, Facebook and Instagram

About Medallia

Medallia (NYSE: MDLA) is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Medallia captures experience signals created on daily journeys in person, on calls and digital channels, over video and social media and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment.www.medallia.com

© 2020 Medallia, Inc. All rights reserved. Medallia®, the Medallia logo, and the names and marks associated with Medallia’s products are trademarks of Medallia. All other trademarks are the property of their respective owners.

PR Contact:

Valerie Beaudett

[email protected]

+1 (650) 400-7833

 

IR Contact:

Carolyn Bass

[email protected]

KEYWORDS: California Utah United States North America

INDUSTRY KEYWORDS: Software Social Media Construction & Property Internet Public Relations/Investor Relations Communications Technology Residential Building & Real Estate

MEDIA:

Posted on

Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

Shockwave’s management is scheduled for a live fireside chat on Wednesday, December 2, 2020, at 8:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the “Investors” section of the company’s website at https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
[email protected]

Investor Contact:
Debbie Kaster
[email protected]

 



Posted on

VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection

VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection

  • Interim data from low-dose cohorts achieved human proof-of-concept, demonstrating restoration of both antibody and T cell responses in chronically-infected hepatitis B (HBV) patients
  • Potent re-stimulation of T cell responses to HBV surface antigens seen in 67% (n=6/9) and 78% (n=7/9) of evaluable patients in the low-dose VBI-2601 unadjuvanted and adjuvanted study arms, respectively
  • Boosting of hepatitis B surface antigen antibodies observed in 60% (6/10) and 67% (6/9) of evaluable patients treated with VBI-2601 unadjuvanted and adjuvanted, respectively
  • Low-dose immunotherapeutic was well-tolerated with no safety signals observed
  • Data from the high-dose cohorts expected in Q1 2021
  • Conference call and webcast scheduled today at 8:30 AM ET

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.

“These early data from the low-dose cohorts are very encouraging and provide a human proof-of-concept that leads us to believe VBI-2601 (BRII-179) could be an effective and critical component of a functional cure for chronic hepatitis B patients,” said Jeff Baxter, VBI’s President and CEO. “A functional cure for chronic hepatitis B is likely to require multiple components sufficient to (1) drive down HBV DNA, (2) drive down immunosuppressive HBV surface antigen, and (3) induce or restore HBV-specific long-term immunologic control against HBV infection. This study was designed to assess the ability of VBI-2601 (BRII-179) to induce or restore antibody and T cell responses against HBV. Responses seen to-date occur rarely in the natural history of this chronically-infected population. We are exploring various combinations of VBI-2601 (BRII-179) with other therapeutic modalities for the next phase of development to achieve functional cure.”

The low-dose cohorts of the ongoing two-part Phase 1b/2a evaluated VBI-2601 (BRII-179), unadjuvanted and adjuvanted, in combination with a nucleos(t)ide analogue (NUC) therapy, intended to reduce HBV DNA, vs. NUC therapy only, in chronically-infected HBV patients. Objectives of this early-stage study were to elicit immunologic responses known to be associated with functional immunity against HBV infection, including the stimulation of T cell immunity and the induction of antibody responses to HBV surface antigens (S, Pre-S1, Pre-S2). The interim data showed:

  • Potent re-stimulation of T cell responses to HBV surface antigens seen in 67% (n=6/9) and 78% (n=7/9) of evaluable patients in the low-dose VBI-2601 unadjuvanted and adjuvanted study arms, respectively
  • Antibody responses against HBV surface antigens were observed in 60% of evaluable patients (n=6/10) in the unadjuvanted cohort and in 67% (n=6/9) in the adjuvanted cohort
  • The low-dose, with and without the adjuvant, was well-tolerated with no safety signals observed

“Recent advances in the development of therapeutics for HBV infection have shown that strong reductions of both HBV DNA and circulating S-antigen are possible, however, restoration of HBV-specific antibody and T cell responses have historically been a challenge, underscoring the importance of a combination with an immunotherapeutic,” said David E. Anderson, Ph.D., VBI’s Chief Scientific Officer. “The levels of immune responses that we were able to elicit with the low dose of VBI-2601 (BRII-179) are an important achievement and we are working hard to be able to provide a solution for patients with such a complex and highly infectious virus.”

The Phase 1b/2a clinical study of VBI-2601 (BRII-179) is a randomized, controlled study designed to assess the safety, tolerability, and antiviral activity of VBI-2601 (BRII-179) in patients with chronic HBV infection. The study is designed as a two-part dose-escalation study assessing a low dose and a high dose of VBI-2601 (BRII-179), with and without an undisclosed adjuvant, and has enrolled 46 patients.

The HBV patients enrolled in the low-dose cohort of the study, including both E+ and E- patients, had baseline mean circulating levels of S-antigen of approximately 3 logs.

This study (ACTRN12619001210167) was conducted by our partner Brii Biosciences. Based on the results from this study, Brii Biosciences is planning to conduct additional combinations studies of VBI-2601 (BRII-179) within Asia-Pacific Economic Cooperation (APEC) and the greater China areas.

Conference Call and Webcast Details

VBI Vaccines will host a conference call and webcast with accompanying slides on Wednesday, November 18, 2020 at 8:30 AM ET. The live webcast and slide presentation can be accessed via the Events/Presentations page in the Investors section of the company’s website, or by clicking this link: https://lifescipartners.zoom.us/webinar/register/WN_2Ax6LpmAQXWSgIqSSM0vlw

A replay of the webcast will be archived on the company’s website for 30 days following the live conference call.

About Hepatitis B

Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://www.vbivaccines.com/investors/

About Brii Biosciences

Brii Biosciences (Brii Bio) is committed to serving patients’ needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People’s Republic of China and the United States, the company is poised to serve as a bridge to deliver transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the health and wellbeing of patients around the world. The company is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and CNS diseases . For more information, visit www.briibio.com.

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

VBI Contact

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: [email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Research Infectious Diseases FDA Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Teledyne Imaging announces development of new generation of CMOS sensors and cameras

THOUSAND OAKS, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Teledyne Imaging, part of Teledyne Technologies, announces the development of a new generation of CMOS sensors and cameras. The initiative involves several groups within Teledyne Imaging, focused on the development, fabrication, and supply of CMOS detectors and cameras for the scientific research and commercial markets including astronomy, soft X-ray, microscopy, spectroscopy and biomedical imaging.

“We are very pleased to launch this new initiative,” states Edwin Roks, Group President of Teledyne Digital Imaging. “This is a natural extension of our legacy of sensor and camera development in both CCD and CMOS, and is designed to meet the needs of emerging markets and applications. It represents the strength of the Teledyne organization, and the value of the acquisition strategy we have implemented, by combining our expertise across several business units, from sensor design to cameras and system interface.”

These new initiatives will meet the increasing demand for higher performing sensor technology by combining essential elements of both CCD and CMOS sensors in a new generation of devices that are distinctly different from anything currently available on the market. Our customers, in nearly every vertical market segment, are asking for the optimal combination of resolution, pixel size, sensitivity and speed. These new designs will include multiple imaging formats up to 66 megapixel, quantum efficiency up to 95%, as well as ultra-low noise and high speed readout. Teledyne will also incorporate their expertise in sensor and electronic cooling to further increase performance.

The project will combine the efforts of multiple groups at Teledyne Digital Imaging segment with over five decades of experience in advanced CCD and CMOS detector and camera technologies. The first sensor and camera prototypes will be available in Q4 2021, with full scale production in 2022.

About Teledyne Imaging

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne Technologies umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage. To register for more information please contact Debby Flint-Baum ([email protected]).

About Teledyne Technologies

Teledyne Technologies is a leading provider of sophisticated instrumentation, digital imaging products and software, aerospace and defense electronics, and engineered systems. Teledyne’s operations are

primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne’s website at www.teledyne.com.

Media
Contact
:

Debby Flint-Baum, Teledyne Imaging
Tel: +1 978 268 0327 | [email protected]



Posted on

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

MENLO PARK, Calif.–(BUSINESS WIRE)–
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.

The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.

NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.

Following are details for the Personalis presentations.

Scientific Poster Presentation

Poster Number

 

Title & Presenter

  

Dates

40

 

 

Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach

Presenter: Simo V. Zhang, PhD

 

NOV 18-19 | Online

Following are details of an industry-sponsored symposium which will be presented at the meeting.

Satellite Symposia

Title

  

Title & Presenter

  

Dates

Sponsored Symposia

  

NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics

Presenters: Erin N. Newburn, PhD and Dan Norton, MBA

 

NOV 18-19 | On Demand

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis®ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

Investor Relations Contact:

Caroline Corner

[email protected]

415-202-5678

Media Contact:

Jennifer Havlek

[email protected]

www.personalis.com

650-752-1300

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Genetics Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Trading Update and 2021 Guidance


Accelerated growth of digital segment, strategic investment in Junior ELT, and cost optimization in adult ELT driving changes to the revenue mix, improved operating efficiency and an expected return to pre-pandemic growth and profitability in 2021

SHENZHEN, China, Nov. 18, 2020 (GLOBE NEWSWIRE) — Meten EdtechX Education Group Ltd. (NASDAQ: METX) (“Meten EdtechX” or the “Company”), a leading omnichannel English language training (“ELT”) service provider in China, provides an update on trading and guidance for 2021, ahead of the release of its unaudited financial results for the third quarter of 2020.

Business Update:

  • Early signs of post-pandemic recovery. Q3 2020 revenue are expected to reach approximately RMB300 million, representing a 60% increase compared with Q2 2020.  Revenue in Q3 2020 is expected to be approximately 29% down compared to Q3 2019 as a result of the mandatory closure of offline learning centers during the first half of 2020 and partial closure or reduced operating hours of certain number of offline learning centers in Q3 2020. To date, all of the Company’s 123 offline learning centers1 have reopened (compared with 103 at the end of August 2020).
  • Strong growth in the Junior ELT/ K12 segment(s). Post-pandemic, the Company has observed customers re-enrolling in Junior ELT, both at offline learning centers and online, at a faster pace than adult customers whose disposable income has been adversely impacted by the pandemic. Junior ELT’s gross billings for Q3 2020 are up 89% compared to the previous quarter (Q2 2020).
  • Streamlining of operations and reallocation of resources to Junior ELT and online ELT segments from adult learning centers.  During the COVID-19 pandemic, the Company has made considerable efforts to reduce its operating costs, aiming to achieve approximately RMB180 million of annual savings. In addition, 70 lease agreements for the self-operated learning centers (nearly 40% of the total leases) were renegotiated and 22 learning centers for adult ELT were closed in order to redeploy the resources to the Junior ELT and online ELT segments. As a result, we estimate our net losses for Q3 2020 to be significantly reduced to approximately RMB40 million (compared with RMB93.4 million in Q2 2020). These cost reduction efforts will continue and are expected to result in a leaner cost structure and a more balanced revenue mix between the offline and online and adult and junior segments by the beginning of 2021.
  • Online offering achieving high growth and profitability.

    Likeshuo
    , Meten EdtechX’s online ELT platform, continues to deliver a strong post-pandemic performance in terms of both growth and profitability, achieving a 54% increase in the number of registered users and a 22% increase in gross billings in Q3 2020 vs Q2 2020. The Company’s online ELT business targets approximately RMB340 million in revenues by the end of 2020, representing a 30% increase compared to full fiscal year of 2019 and approximately RMB16 million of net profit (vs RMB1.5 million for the previous year). Meten EdtechX’s omnichannel platform and rising Likeshuo brand awareness continue to provide the Company with a competitive advantage in terms of customer acquisition.
  • Continued Product innovation. Meten EdtechX continues to invest in product development and has recently launched several new products across both its offline and online platforms. This includes two new language (Japanese and Spanish) products, K12 junior products and the “Bi Gao” exam preparatory product for middle schoolers. 

________________________

1 Inclusive of the permanently closed 11 learning centers for adult ELT.

Guidance 2021

  • “Return to normal” scenario expected by end of 2021: improved profitability and continued digital shift. Assuming no resurgence of the COVID-19 pandemic in China, and taking into account recent positive developments relating to a COVID-19 vaccine and the continuous recovery of China’s economy, Meten EdtechX expects its trading and profitability to gradually return to pre-pandemic levels over the course of 2021. While this remains partially dependent on the pace at which the adult ELT market recovers, the Company’s gross billing target for FY 2021 is expected to be within the range of RMB1.5-1.6 billion (representing a return to pre-pandemic level), approximately 40-50% of which are driven by Likeshuo. The Company is currently aiming for EBITDA of RMB200 million and net profit of RMB120 million for the FY 2021, respectively.
  • Selective review of consolidation opportunities. Meten EdtechX continues to see a compelling case for consolidation in the language, K12 and future skills training in China and Asia more generally, and will continue to selectively consider merger and joint venture opportunities.   

Alan Peng, CEO of the Company commented:

“Meten EdtechX and the wider ELT market in China are gradually recovering from the COVID-19 pandemic, though trading conditions in the second part of 2020 remain challenging for our core ELT adult offline business.

Despite these challenges and losses incurred during the year, we continue to strongly believe that China remains fundamentally a high growth market for the ELT sector, and our diversified omnichannel offering and strategic footprint in tier 2, 3 and 4 cities give us a significant competitive advantage. During 2020, we have taken decisive and necessary action to ensure we emerge in 2021 in a stronger position with a leaner cost structure, enhanced operating efficiency and increased exposure to the higher growth segments of junior/K12 and online business segments.

We will continue to provide trading updates to the market on a regular basis as the situation evolves.  Our unaudited financial results for the third quarter of 2020 will be released in early December. We are also committed to establishing equity research coverage of our stock in 2021, so that our overall performance and the acceleration of our digital growth are benchmarked with other market peers.”

The above
business update and guidance for 2021
reflect Meten EdtechX’s current and preliminary view, which is subject to uncertainty and change.

For investor and media enquiries, please contact:

Citigate Dewe Rogerson

[email protected]

+44 (0)20 7025 6400

About Meten EdtechX

Meten EdtechX is a leading ELT service provider in China, delivering English language and future skills training for Chinese students and professionals. Through a sophisticated digital platform and nationwide network of learning centers, the Company provides its services under three industry-leading brands: Meten (adult and junior ELT services), ABC (primarily junior ELT services) and Likeshuo (online ELT). It offers superior teaching quality and student satisfaction, which are underpinned by cutting edge technology deployed across its business, including AI-driven centralized teaching and management systems that record and analyze learning processes in real time.

The Company is committed to improving the overall English language competence and competitiveness of the Chinese population to keep abreast of the rapid development of globalization. Its experienced management is focused on further developing its digital platform and expanding its network of learning centers to deliver a continually evolving service offerings to a growing number of students across China.


Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business update and guidance for 2021 in this announcement, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the impact of the COVID-19 outbreak, our ability to attract students without a significant decrease in course fees; our ability to continue to hire, train and retain qualified teachers; our ability to maintain and enhance our “Meten” brand; our ability to effectively and efficiently manage the expansion of our school network and successfully execute our growth strategy; the outcome of ongoing, or any future, litigation or arbitration, including those relating to copyright and other intellectual property rights; competition in the English language training sector in China; changes in our revenues and certain cost or expense items as a percentage of our revenues; the expected growth of the Chinese English language training and private education market; Chinese governmental policies relating to private educational services and providers of such services; health epidemics and other outbreaks in China; and general economic conditions in China. Further information regarding these and other risks is included in our annual report on Form 20-F and other documents filed with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no duty to update such information, except as required under applicable law.